X4 Pharmaceuticals Inc’s recently made public that its Executive Chairman Craig Adam R acquired Company’s shares for reported $0.25 million on Oct 23 ’25. In the deal valued at $2.90 per share,86,206 shares were bought. As a result of this transaction, Craig Adam R now holds 376,087 shares worth roughly $1.41 million.
Then, Baldry Mark bought 1,032 shares, generating $2,561 in total proceeds. Upon buying the shares at $2.48, the Chief Commercial Officer now owns 25,337 shares.
Before that, Baldry Mark bought 13,404 shares. X4 Pharmaceuticals Inc shares valued at $4,598 were divested by the Chief Commercial Officer at a price of $0.34 per share. As a result of the transaction, Baldry Mark now holds 129,173 shares, worth roughly $0.48 million.
B. Riley Securities downgraded its X4 Pharmaceuticals Inc [XFOR] rating to a Neutral from a a Buy in a research note published on December 12, 2023; the price target was decreased to $1 from $3. Cantor Fitzgerald began covering XFOR with “an Overweight” recommendation on December 22, 2022. Piper Sandler started covering the stock on December 12, 2022. It rated XFOR as “an Overweight”.
Price Performance Review of XFOR
On Monday, X4 Pharmaceuticals Inc [NASDAQ:XFOR] saw its stock fall -1.58% to $3.74. Over the last five days, the stock has gained 19.11%. X4 Pharmaceuticals Inc shares have fallen nearly -75.28% since the year began. Nevertheless, the stocks have fallen -83.01% over the past one year. While a 52-week high of $26.83 was reached on 01/02/25, a 52-week low of $1.35 was recorded on 08/11/25.
Levels Of Support And Resistance For XFOR Stock
The 24-hour chart illustrates a support level at 3.61, which if violated will result in even more drops to 3.48. On the upside, there is a resistance level at 3.92. A further resistance level may holdings at 4.10.
How much short interest is there in X4 Pharmaceuticals Inc?
A steep rise in short interest was recorded in X4 Pharmaceuticals Inc stocks on 2025-10-15, dropping by -0.11 million shares to a total of 1.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 1.89 million shares. There was a decline of -6.0%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 23, 2019 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $20 price target.
